Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas E Feltner

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Innovations in Clinical Neuroscience|May 16, 2015
Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 SymposiumJared W Young, William Z Potter, Steve Riley, et al.
Journal of Market Access & Health Policy|May 21, 2019
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patientsDaniel C Malone, Rebecca Dean, Ramesh Arjunji, et al.
Innovations in Clinical Neuroscience|July 25, 2013
Study Site Experiences and Attitudes Toward Prospective Assessments of Suicidal Ideation and Behavior in Clinical Trials: Results of an Internet-based SurveyMichelle Stewart, Adam Butler, Larry Alphs, et al.
Journal of Clinical Psychopharmacology|June 27, 2003
A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorderDouglas E Feltner, Jerri G Crockatt, Steven J Dubovsky, et al.
Archives of General Psychiatry|September 7, 2005
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolamKarl Rickels, Mark H Pollack, Douglas E Feltner, et al.
Journal of Market Access & Health Policy|March 12, 2021
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)Rebecca Dean, Ivar Jensen, Phil Cyr, et al.
The American Journal of Psychiatry|March 4, 2003
Pregabalin in generalized anxiety disorder: a placebo-controlled trialAtul C Pande, Jerri G Crockatt, Douglas E Feltner, et al.
Journal of Clinical Psychopharmacology|June 23, 2004
Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter studyAtul C Pande, Douglas E Feltner, James W Jefferson, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2005
How modeling and simulation have enhanced decision making in new drug developmentRaymond Miller, Wayne Ewy, Brian W Corrigan, et al.
Pediatric Neurology|July 7, 2019
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement TherapyLinda P Lowes, Lindsay N Alfano, W David Arnold, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Innovations in Clinical Neuroscience|May 16, 2015
Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 SymposiumJared W Young, William Z Potter, Steve Riley, et al.
Journal of Market Access & Health Policy|May 21, 2019
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patientsDaniel C Malone, Rebecca Dean, Ramesh Arjunji, et al.
Innovations in Clinical Neuroscience|July 25, 2013
Study Site Experiences and Attitudes Toward Prospective Assessments of Suicidal Ideation and Behavior in Clinical Trials: Results of an Internet-based SurveyMichelle Stewart, Adam Butler, Larry Alphs, et al.
Journal of Clinical Psychopharmacology|June 27, 2003
A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorderDouglas E Feltner, Jerri G Crockatt, Steven J Dubovsky, et al.
Archives of General Psychiatry|September 7, 2005
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolamKarl Rickels, Mark H Pollack, Douglas E Feltner, et al.
Journal of Market Access & Health Policy|March 12, 2021
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)Rebecca Dean, Ivar Jensen, Phil Cyr, et al.
The American Journal of Psychiatry|March 4, 2003
Pregabalin in generalized anxiety disorder: a placebo-controlled trialAtul C Pande, Jerri G Crockatt, Douglas E Feltner, et al.
Journal of Clinical Psychopharmacology|June 23, 2004
Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter studyAtul C Pande, Douglas E Feltner, James W Jefferson, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2005
How modeling and simulation have enhanced decision making in new drug developmentRaymond Miller, Wayne Ewy, Brian W Corrigan, et al.
Pediatric Neurology|July 7, 2019
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement TherapyLinda P Lowes, Lindsay N Alfano, W David Arnold, et al.
Pageof 3